SLNCF 8-K SEC Filing Analysis

Latest settled — T+20d

SLNCF ▼ -59.70% at T+20d

NEUTRAL call ✗ call lost -59.70% · α vs SPY -62.83% · entry $2.63 → $1.06

Next anchor: T+60d in 7w

Currently $1.06 · -59.70% from $2.63 entry

Entry anchored
May 7, 2026
via day open

T+1d

0.00%

call 0.00% · α -0.83%

$2.63

settled 5w ago

T+5d

-44.77%

call -44.77% · α -46.28%

$1.45

settled 4w ago

T+20d

-59.70%

call -59.70% · α -62.83%

$1.06

settled 8d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Silence Therapeutics reported Q1 2026 revenue of $0.4M vs consensus $1.5M, a significant miss reflecting early-stage biotech volatility. Net loss narrowed to $15.0M ($0.11 per share) from $28.5M YoY, driven by lower R&D spend. The key catalyst remains Phase 2 SANRECO topline in August 2026.

Actionable Insight

The stock will trade on SANRECO Phase 2 readout in August 2026, not Q1 financials. Monitor abstract presentations at EHA (June) and EAS (May) for additional pipeline signals.

Key Facts

Q1 2026 revenue $0.4M; consensus was $1.5M (miss)
Net loss $15.0M vs $28.5M YoY, improvement due to lower R&D expenses
Cash & investments $70.1M as of March 31, 2026
Phase 2 SANRECO trial (divesiran) on track for topline results in August 2026
SLN312 Phase 1 abstract accepted for late-breaking oral at EAS Congress

Financial Impact

Revenue miss of $1.1M (73% below consensus) but pre-revenue biotech; cash burn manageable

revenuenet losscash position

Risk Factors

Phase 2 SANRECO trial failure or delay
Cash runway only ~12 quarters at current burn rate without additional partnering or financing

Market Snapshot

Exchange

OTC

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-210428
Document: sln-20260507.htm	0001193125-26-210428
Document: 0001193125-26-210428-index-headers.html	0001193125-26-210428
Document: 0001193125-26-210428-index.html	0001193125-26-210428
Document: 0001193125-26-210428.txt	0001193125-26-210428
8-K Data (Synthetic)	0001193125-26-210428

4 reports for SLNCF

T+1T+5T+20T+60

33% Hit rate 1 of 3 directional calls best @ T+1▲ +27.02%May 18, 2026

Filters

Reports for SLNCF — sortable, filterable
	Type				Now
May 28, 2026 16d ago	EFFECT BEARISH ★ 5/10	$1.06 $1.06	· 0.00%	▲ +0.32%	$1.06 (+0.00%)
May 27, 2026 16d ago	424B5 BEARISH ★ 6/10	$1.06 $1.06	· 0.00%	▲ +0.32%	$1.06 (+0.00%)
May 18, 2026 25d ago	S-3 BEARISH ★ 6/10	$1.45 $1.06	▲ +27.02%	▲ +29.32%	$1.06 (+27.02%)
May 7, 2026 5w ago	8-K NEUTRAL ★ 4/10	$2.63 $1.45	▼ −44.77%	▼ −46.28%	$1.06 (−59.70%)

US Market Status

Market Closed — Opens Mon (48h 50m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access